Work

123P Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers

Year: 2024

Type: article

Abstract: Conclusions: In this study population, the addition of antieIL-8 to NIVO + IPI was well tolerated, but no statistically significant difference for the primary endpoint of ORR or the secondary endpoint of PFS was observed in patients with advanced melanoma who had progressed on/after anti-PD-(L)1 therapy.Clinical trial identification: NCT03400332.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100752

Authors: T. O'Hare, J. Cleveland, V.M. Jansen, D. Dornan

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170

Funders: AstraZeneca, PharmaMar, CRIS Cancer Foundation